Business Model & Revenue
Xencor is a clinical-stage biopharmaceutical company built on its XmAb protein-engineering platform, which modifies Fc domains and antibody architectures to create bispecific antibodies, antibody-drug conjugate candidates and optimized biologics. The company earns revenue today not from products but from collaboration economics: non-cash royalty revenue from partners including Incyte and Alexion (whose Ultomiris uses Xencor's Xtend Fc technology), milestones, and license fees. The July 2026 settlement with Alexion, worth $105 million in two $52.5 million payments, converted a disputed Ultomiris U.S. royalty stream into contracted cash.
The investment case is a barbell: near-term, royalties and milestone payments from partnered programs subsidize the burn; long-term, wholly owned assets such as XmAb819 (ENPP3 x CD3 in ccRCC) and the broader oncology and autoimmune portfolios create the upside. XmAb819 exemplifies the 2+1 bispecific format — one CD3 arm for T-cell recruitment, two lower-affinity tumor-targeting arms — designed to engage malignant cells selectively while limiting systemic T-cell activation. Success in solid tumors with a T-cell engager would be a genuine first for the modality and would re-rate the entire platform.
Financial Highlights
Second Quarter 2026 Results (Quarter Ended June 30, 2026)
| Metric | Q2 2026 | Q2 2025 | YoY% |
|---|---|---|---|
| Revenue | $51.2M | $43.6M | +17.4% |
| Net Loss | $(21.7)M | $(30.8)M | Loss narrowed 29.5% |
| Diluted EPS | $(0.29) | $(0.41) | Loss narrowed 29.3% |
| Cash & Marketable Securities | $486.4M | $610.8M (Dec 31, 2025) | -20.4% |
Revenue is primarily non-cash royalty revenue from Incyte and Alexion collaborations tied to Xencor's engineered-antibody technology.
Balance Sheet Snapshot
| Item | Amount |
|---|---|
| Cash & Marketable Securities | $486.4M |
| Alexion Settlement Receivable | $52.5M second payment due August 2027 |
| Shares Outstanding | ≈55.4M |
Guidance: Xencor expects to end 2026 with $420-440 million in cash, cash equivalents and marketable debt securities (raised from $380-400 million after the July 2026 Alexion settlement), with runway into 2029.
Competitive Landscape
XmAb819 targets advanced clear cell renal cell carcinoma after PD-(L)1 and VEGFR TKI therapy, a niche where no ENPP3-directed agent exists. Standard of care in later lines is a crowded field of tyrosine kinase inhibitors and combinations, and a new mechanism with confirmed responses in triple-class-exposed patients would be commercially distinctive.
- Exelixis (EXEL): Cabozantinib franchises the VEGFR TKI class across RCC lines; an entrenched oral option XmAb819 would face head-to-head.
- Bristol Myers Squibb (BMY): Nivolumab-based combinations dominate front-line ccRCC; BMS also owns the IDH1 paragon of late-line orphan oncology economics.
- Merck (MRK): Pembrolizumab combinations plus belzutifan (HIF2a) push novel mechanisms earlier; 34% of XmAb819 patients had already seen a HIF2a inhibitor, underscoring the unmet need beyond them.
- Aveo Oncology / LG Chem: Tivozanib (FOTIVDA) is the designated Phase 3 control arm, a low bar at 10.5% cORR and 5.4 months median PFS in TiNivo-2.
- Roche (RHHBY): The CEA-CD3 bispecific cibisatamab lineage proves Big Pharma's interest in solid-tumor T-cell engagers; none has reached RCC.
Moats:
- First-in-class ENPP3 x CD3 positioning with dose-response and durability data no competitor can replicate quickly.
- The XmAb engineering platform, validated by approved-partner products (Ultomiris) that fund R&D through royalties.
- A cash runway into 2029 that removes forced-dilution dynamics common to clinical-stage peers.
Catalysts
- Maturation of the 400 mcg/kg cohort to at least 20 efficacy-evaluable patients, supporting final dose selection in 1H 2027.
- FDA discussions on a potential accelerated approval pathway in exhausted-standard-of-care ccRCC subgroups, planned for 1H 2027.
- Initiation of the global randomized Phase 3 of XmAb819 monotherapy versus tivozanib in post PD-(L)1 / post-VEGFR TKI ccRCC.
- Proof-of-concept sub-study readouts enabling expansion into additional ENPP3-expressing tumor types.
- Q3 2026 financial results (November 2026) updating cash guidance after the first $52.5 million Alexion settlement payment.
Key Risks
- Clinical risk: the 400 mcg/kg cohort is small (n=11 evaluable) with a wide confidence interval, and the 45.5% cORR may not hold as the cohort matures toward the planned 20-patient data set in 1H 2027.
- Regulatory risk: the FDA may not grant an accelerated approval pathway in post PD-(L)1 / post-VEGFR TKI ccRCC, and the planned randomized Phase 3 versus tivozanib could fail to demonstrate superiority.
- Safety risk: Grade 3 or higher related TEAEs occurred in 72.1% of expansion patients, including liver enzyme elevations and cytokine release syndrome inherent to CD3 T-cell engagers.
- Competitive risk: entrenched checkpoint inhibitor, VEGFR TKI and HIF2a inhibitor combinations could crowd out a new mechanism in later-line ccRCC or move into earlier settings first.
- Financial risk: a multi-program burn rate means the runway into 2029 assumes royalty receipts including the second $52.5 million Alexion payment; setbacks could compress the runway and force dilution.
Our Thesis
What the market is missing is how quickly XmAb819 has moved from mechanism to medicine. The Phase 1 enrolled 119 heavily pretreated ccRCC patients across 11 intravenous dose levels, and response rates climbed monotonically with dose (30% at 100 mcg/kg, 44% at 200, 45.5% confirmed at 400) — the signature of a genuinely active agent. In the pooled subgroup that failed a PD-(L)1 inhibitor and two or more VEGFR TKIs (n=42), the confirmed response rate was 45%, where the tivozanib arm of TiNivo-2 produced a 10.5% cORR and 5.4 months median PFS. Management guided to registration-enabling development by end of 2027, and XmAb819 is the third XmAb 2+1 bispecific to reach late-stage development, validating a platform already monetized through Ultomiris and Incyte royalties.
Our $45.00 target implies a $2.49 billion market cap on 55.4 million shares; net of a projected $420-440 million year-end cash position, enterprise value is roughly $2.05 billion. We build that as a 55% probability-weighted present value of about $3.5 billion for XmAb819 alone if it wins a 2L/3L ccRCC position (about $650 million peak sales mid-2030s), or about $1.9 billion risk-adjusted, plus roughly $0.4 billion for the rest of the pipeline and royalties. The rating is Speculative because the 400 mcg/kg cohort holds just 11 efficacy-evaluable patients today; the thesis de-risks when the 20-patient data set lands in 1H 2027.
Get reports like this delivered free
New small-cap research every week. No paywall, no fluff.